Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Frontotemporal behavioral scale

F Lebert1, F Pasquier, L Souliez

  • 1Memory Disorders Unit, Centre Hospitalier Régional Universitaire, Lille, France.

Alzheimer Disease and Associated Disorders
|January 7, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The pattern of cortical thickness associated with executive dysfunction in MCI and SCC: The MEMENTO cohort.

Revue neurologique·2024
Same author

Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.

The journal of prevention of Alzheimer's disease..·2024
Same author

Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.

Leukemia & lymphoma·2020
Same author

Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.

Drugs of today (Barcelona, Spain : 1998)·2020
Same author

17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression.

Molecular psychiatry·2016
Same journal

More Publications Needed on Cognitively Impaired-Not MCI: Call for Papers.

Alzheimer disease and associated disorders·2026
Same journal

CHMP2B p.Ala30Ser Variant in Biomarker-Confirmed Early-Onset Alzheimer Disease: A Potential Endolysosomal Disease Modifier.

Alzheimer disease and associated disorders·2026
Same journal

Early Gut Microbiome Alterations in Mild Cognitive Impairment Reflect Changes in Alzheimer Disease.

Alzheimer disease and associated disorders·2026
Same journal

Improvements in Cogstate Test Performance Depend on Number and Frequency of Prior Tests: Evidence from a Randomized Follow-Up Design.

Alzheimer disease and associated disorders·2026
Same journal

Identification of Functional lncRNAs in Alzheimer Disease by Integrative Analysis of lncRNA-mRNA Network Based on Competing Endogenous RNA Mechanism.

Alzheimer disease and associated disorders·2026
Same journal

Valacyclovir Treatment in Mild Cognitive Impairment: The VALMCI Randomized Clinical Trial.

Alzheimer disease and associated disorders·2026
See all related articles

Frontotemporal dementia (FTD) is often misdiagnosed. A new behavioral scale effectively identifies early FTD, distinguishing it from Alzheimer disease and vascular dementia with high accuracy.

Area of Science:

  • Neurology
  • Neuroscience
  • Geriatrics

Background:

  • Frontotemporal dementia (FTD) comprises up to 20% of degenerative dementia cases but is frequently underrecognized and misdiagnosed as Alzheimer disease (AD) or vascular dementia (VaD).
  • Misdiagnosis of FTD can significantly impact the outcomes and validity of AD clinical trials.
  • Behavioral abnormalities are the primary presenting symptoms of FTD.

Purpose of the Study:

  • To evaluate a novel behavioral scale designed to assess frontal lobe dysfunction.
  • To establish a specific behavioral cutoff score for the early diagnosis of FTD.
  • To differentiate FTD from AD and VaD based on behavioral assessments.

Main Methods:

  • Development and application of the behavioral frontotemporal lobe dysfunction assessment scale.

Related Experiment Videos

  • Statistical analysis to compare scale scores between FTD and other dementia groups (AD, VaD).
  • Determination of diagnostic sensitivity and specificity using a defined cutoff score.

    • Main Results:

    • The behavioral frontotemporal lobe dysfunction assessment scale yielded significantly higher scores in FTD patients compared to those with AD or VaD (p < 0.0001).
    • A cutoff score of 3 points on the scale achieved 91% sensitivity and 95% specificity for diagnosing FTD.
    • Noncognitive symptoms, recognized as institutionalization factors, may differ across dementia etiologies.

    Conclusions:

    • The validated behavioral scale offers a reliable tool for the early and accurate diagnosis of FTD.
    • Implementing this scale can improve diagnostic precision, reducing misclassification with AD and VaD.
    • Enhanced diagnostic accuracy for FTD is crucial for patient management and clinical trial integrity.